<DOC>
	<DOCNO>NCT02969473</DOCNO>
	<brief_summary>In phase II study , investigator aim evaluate efficacy toxicity definitive concurrent chemoradiotherapy ( CCRT ) docetaxel plus cisplatin ( DP regimen ) versus 5-fluorouracil plus cisplatin ( PF regimen ) patient esophageal squamous cell carcinoma ( ESCC ) .</brief_summary>
	<brief_title>Definitive Concurrent Chemoradiotherapy With Docetaxel Plus Cisplatin Versus 5-fluorouracil Plus Cisplatin Patients With Esophageal Squamous Cell Carcinoma</brief_title>
	<detailed_description>Esophageal cancer one fatal malignancy worldwide . Radical surgery primary treatment patient resectable esophageal cancer . For medically unfit patient medically fit patient decline surgery , definitive radiotherapy plus concurrent chemotherapy establish standard treatment . Since 1980 ' , widely use chemotherapeutic regimen combination radiotherapy esophageal cancer cisplatin ( CDDP ) plus 5-fluorouracil ( 5-FU ) ( PF regimen ) . However , locoregionally persistent recurrent disease still quite common survival remain poor . Several previous study conduct radiation therapy oncology group ( RTOG ) explore efficacy radiation dose escalation , result turn disappointing . And study incorporate intensified PF regimen new-generation cytotoxic agent paclitaxel oxaliplatin show advantage standard-dosage PF regimen either . In phase II study , investigator aim evaluate efficacy toxicity definitive concurrent chemoradiotherapy ( CCRT ) docetaxel plus cisplatin ( DP regimen ) versus 5-fluorouracil plus cisplatin ( PF regimen ) patient esophageal squamous cell carcinoma ( ESCC ) .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>patient histologically proven squamous cell carcinoma esophagus stage IIIVA disease , include metastatic celiac cervical node , accord sixth edition American Joint Committee Cancer ( AJCC ) stag system esophageal cancer age 18 70 year Karnofsky Performance Status ( KPS ) score ≥ 70 adequate bone marrow function ( leukocyte count ≥ 4000/uL , platelet count ≥ 100,000/uL ) , adequate liver function ( serum alanine aminotransferase ( ALT ) level serum aspartate aminotransferase ( AST ) level &lt; twice upper limit normal , serum bilirubin level &lt; 1.5 mg/dL ) , adequate renal function ( creatinine clearance ≥ 50 mL/min ) serious medical condition life expectancy ≥ 3 month write informed consent detection distant metastasis ( exclude metastatic celiac cervical node ) treatment treatment know allergy CDDP , 5FU , docetaxel pregnancy breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>esophageal squamous cell carcinoma</keyword>
	<keyword>concurrent chemoradiotherapy</keyword>
	<keyword>docetaxel</keyword>
	<keyword>cisplatin</keyword>
	<keyword>5-fluorouracil</keyword>
</DOC>